A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

NCT05318339 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Transitional Cell
HER-2 Gene Amplification

Interventions

DRUG: Trastuzumab

Sponsor

Chinese Academy of Medical Sciences